1. Fusariosis manifesting as targetoid purpuric cutaneous lesions in immunocompromised patients. (28th May 2020) Authors: Erdemoglu, Y.; Aydingoz, I.E.; Ustun, C.; Uzay, A.; Besli, Y.; Ozturk Durmaz, E.; Demirkesen, C.; Sahin, S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 11(2020) Page Start: e734 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1049: A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS. (23rd June 2022) Authors: DeAngelo, D. J.; Pullarkat, V.; Piris-Villaespesa, M.; George, T. I.; Patel, J. L.; Ustun, C.; Bose, P.; Heaney, M. L.; Pilla, A.; Massaro, M.; Exter, B.; Jolin, H. A.; Mikhak, Z.; Tashi, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 939 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗